Literature DB >> 10208709

Insomnia.

M Eddy1, G S Walbroehl.   

Abstract

Insomnia is a common complaint with potentially significant medical and psychologic complications. In some cases insomnia presents as a symptom of another underlying medical, psychiatric or environmental condition. In these cases, management of insomnia depends on accurate diagnosis and successful treatment of the underlying condition. In other cases, insomnia is a primary disorder requiring direct treatment. Pharmacologic treatments include nonprescription medications, sedating tricyclic antidepressants, benzodiazepines and related drugs. Behavior management methods that may be administered in the office setting include stimulus control therapy, sleep restriction therapy and sleep hygiene education. Although prescription medications and behavior therapy have similar short-term efficacy, behavior interventions are recommended as the first line of treatment for primary insomnia because of their greater safety and long-term efficacy.

Entities:  

Mesh:

Year:  1999        PMID: 10208709

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

1.  Sleep quality and disease severity in patients with chronic rhinosinusitis.

Authors:  Jeremiah A Alt; Timothy L Smith; Jess C Mace; Zachary M Soler
Journal:  Laryngoscope       Date:  2013-08-05       Impact factor: 3.325

2.  Sleep quality and associated factors in ankylosing spondylitis: relationship with disease parameters, psychological status and quality of life.

Authors:  İbrahim Batmaz; Mustafa Akif Sarıyıldız; Banu Dilek; Yasin Bez; Mehmet Karakoç; Remzi Çevik
Journal:  Rheumatol Int       Date:  2012-09-02       Impact factor: 2.631

3.  Genetic variants in RBFOX3 are associated with sleep latency.

Authors:  Najaf Amin; Karla V Allebrandt; Ashley van der Spek; Bertram Müller-Myhsok; Karin Hek; Maris Teder-Laving; Caroline Hayward; Tõnu Esko; Josine G van Mill; Hamdi Mbarek; Nathaniel F Watson; Scott A Melville; Fabiola M Del Greco; Enda M Byrne; Edwin Oole; Ivana Kolcic; Ting-Hsu Chen; Daniel S Evans; Josef Coresh; Nicole Vogelzangs; Juha Karjalainen; Gonneke Willemsen; Sina A Gharib; Lina Zgaga; Evelin Mihailov; Katie L Stone; Harry Campbell; Rutger Ww Brouwer; Ayse Demirkan; Aaron Isaacs; Zoran Dogas; Kristin D Marciante; Susan Campbell; Fran Borovecki; Annemarie I Luik; Man Li; Jouke Jan Hottenga; Jennifer E Huffman; Mirjam Cgn van den Hout; Steven R Cummings; Yurii S Aulchenko; Philip R Gehrman; André G Uitterlinden; Heinz-Erich Wichmann; Martina Müller-Nurasyid; Rudolf Sn Fehrmann; Grant W Montgomery; Albert Hofman; Wen Hong Linda Kao; Ben A Oostra; Alan F Wright; Jacqueline M Vink; James F Wilson; Peter P Pramstaller; Andrew A Hicks; Ozren Polasek; Naresh M Punjabi; Susan Redline; Bruce M Psaty; Andrew C Heath; Martha Merrow; Gregory J Tranah; Daniel J Gottlieb; Dorret I Boomsma; Nicholas G Martin; Igor Rudan; Henning Tiemeier; Wilfred Fj van IJcken; Brenda W Penninx; Andres Metspalu; Thomas Meitinger; Lude Franke; Till Roenneberg; Cornelia M van Duijn
Journal:  Eur J Hum Genet       Date:  2016-05-04       Impact factor: 4.246

4.  Indiplon in the treatment of sleep disorders.

Authors:  Alan Lankford
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.